Novartis_1612 - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Novartis asthma drug fevipiprant fails in Phase III trials

Novartis_1612
Novartis studied fevipiprant for the treatment of patients with moderate-to-severe asthma. Credit: Novartis AG.